SCHEMBL25412424

SCHEMBL25412424

Cc1ccc(S(=O)(=O)N2CC(Cc3ccccc3)c3c(C=O)ccc(F)c32)cc1

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 1/20 0.39
▸ NLRP3 Q96P20 1/20 0.39
▸ CMA1 P23946 3/20 0.38
▸ KDM4E B2RXH2 2/20 0.38
▸ UBE2N P61088 1/20 0.38
▸ GAA P10253 2/20 0.35
▸ PKM P14618 1/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ FOLH1 Q04609 1/20 0.34
▸ MMP2 P08253 1/20 0.34
▸ CAPN1 P07384 2/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ ELANE P08246 1/20 0.34
▸ HTR6 P50406 1/20 0.34
▸ MAPK1 P28482 1/20 0.34
▸ ATM Q13315 1/20 0.34
▸ CTSB P07858 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25412418 1.00 ALDH1A1 (0.39) ALDH1A1NLRP3CMA1KDM4EUBE2N
SCHEMBL26307919 0.86 MMP2 (0.37) ALDH1A1KDM4EUBE2NPKMMMP2
SCHEMBL25409814 0.86 MEN1 (0.41) ALDH1A1NLRP3CMA1KDM4EUBE2N
SCHEMBL25409822 0.86 MEN1 (0.41) ALDH1A1NLRP3CMA1KDM4EUBE2N
SCHEMBL25411871 0.83 ALDH1A1 (0.39) ALDH1A1NLRP3CMA1GAAPKM
SCHEMBL25411864 0.83 ALDH1A1 (0.39) ALDH1A1NLRP3CMA1GAAPKM
SCHEMBL25411450 0.82 ALDH1A1 (0.40) ALDH1A1NLRP3CMA1KDM4EUBE2N
SCHEMBL25411441 0.82 ALDH1A1 (0.40) ALDH1A1NLRP3CMA1KDM4EUBE2N
SCHEMBL25410638 0.81 ALDH1A1 (0.38) ALDH1A1NLRP3CMA1KDM4EUBE2N
SCHEMBL25410631 0.81 ALDH1A1 (0.38) ALDH1A1NLRP3CMA1KDM4EUBE2N

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230278959-A1 Synthesis of Optically Active Indoline Derivatives Via Ruthenium(II)-Catalyzed Enantioselective C-H Functionalization MISSISSIPPI STATE UNIVERSITY 2023-09-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230278959-A1 Synthesis of Optically Active Indoline Derivatives Via Ruthenium(II)-Catalyzed Enantioselective C-H Functionalization INMT, IDO2, WEE2 ALDH1A1 3453/4885NLRP3 2466/4885CMA1 1751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback